OpGen provided a business update including preliminary top-line Q222 results. Quarterly revenues of $1.0m increased 23.2% y-o-y from $0.8m in Q121 and 113% from the previous quarter. Management highlighted several key developments, including the first commercial contract for the Acuitas AMR Gene Panel, extension of the existing distribution agreement with European distribution partner Menarini, a new distribution agreement with Leader Life Sciences for UAE and Qatar, and an at-the-market (ATM) s ....
11 Jul 2022
OpGen - A catalyst-rich Q222
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
OpGen - A catalyst-rich Q222
- Published:
11 Jul 2022 -
Author:
Soo Romanoff -
Pages:
2
OpGen provided a business update including preliminary top-line Q222 results. Quarterly revenues of $1.0m increased 23.2% y-o-y from $0.8m in Q121 and 113% from the previous quarter. Management highlighted several key developments, including the first commercial contract for the Acuitas AMR Gene Panel, extension of the existing distribution agreement with European distribution partner Menarini, a new distribution agreement with Leader Life Sciences for UAE and Qatar, and an at-the-market (ATM) s ....